BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Gastrointestinal Cancer
Conditions
Advanced Gastrointestinal Cancer
Trial Timeline
Jan 1, 2014 → Nov 1, 2019
NCT ID
NCT02024607About BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib is a phase 1/2 stage product being developed by Sumitomo Pharma for Advanced Gastrointestinal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02024607. Target conditions include Advanced Gastrointestinal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02024607 | Phase 1/2 | Completed |
Competing Products
20 competing products in Advanced Gastrointestinal Cancer